File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong

TitleHigh prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong
Authors
KeywordsEnfuvirtide
Gp41
HAART
HIV
Issue Date2010
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcv
Citation
Journal Of Clinical Virology, 2010, v. 47 n. 3, p. 273-275 How to Cite?
AbstractBackground: Enfuvirtide (ENF) is a viral fusion inhibitor used in patients failing highly active antiretroviral therapy (HAART). Mutations associated with ENF resistance have been identified within amino acid positions 36-45 of gp41. As ENF will be introduced to Hong Kong, an understanding of the prevalence of naturally occurred ENF resistance mutations is important before implementation of ENF treatment. Objectives: To investigate the prevalence of ENF resistance-associated mutations in the HR1 and HR2 of HIV-1 strains obtained from ENF-naïve patients. Study design: HIV-1 strains isolated from 185 patients (156 antiretroviral treatment [ART]-naïve and 29 HAART-experienced) were screened for ENF resistance-associated mutations using RT-PCR and DNA sequencing. Results: Primary mutations were detected in 19.4% of HARRT-experienced patients and 20.5% of ART-naïve patients. G36D was encountered most frequently and more prevalent in non-B subtypes. N42S, L54 M and V69I were the major polymorphisms detected. N42S and L54M were predominant in CRF01_AE and subtype B, respectively. V69I was found in all samples harboring G36D. In three longitudinal samples from an ENF-treated patient, G36D was detected after ENF treatment for 6 months and the mutation persisted after termination of ENF for 6 months. Conclusions: The high prevalence of ENF resistance-associated mutations in HARRT-experienced and ART-naïve patients identified in this study highlights the importance of mutation screening before ENF therapy in Hong Kong. Our findings from the ENF-treated patient showed that G36D mutation persisted as long as 6 months after ENF withdrawal. Phenotypic assays will be necessary to confirm the influence of this mutation to ENF susceptibility. © 2010 Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/125562
ISSN
2015 Impact Factor: 2.647
2015 SCImago Journal Rankings: 1.503
ISI Accession Number ID
Funding AgencyGrant Number
AIDS Trust Fund of the Hong Kong Special Administrative Region (HKSAR) GovernmentMSS-152R
155R
164R
Funding Information:

The study was supported by the AIDS Trust Fund of the Hong Kong Special Administrative Region (HKSAR) Government (Grant MSS-152R, 155R and 164R).

References

 

DC FieldValueLanguage
dc.contributor.authorLeung, PHMen_HK
dc.contributor.authorChen, JHKen_HK
dc.contributor.authorWong, KHen_HK
dc.contributor.authorChan, KCen_HK
dc.contributor.authorLam, HYen_HK
dc.contributor.authorCheng, VCCen_HK
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorYam, WCen_HK
dc.date.accessioned2010-10-31T11:38:25Z-
dc.date.available2010-10-31T11:38:25Z-
dc.date.issued2010en_HK
dc.identifier.citationJournal Of Clinical Virology, 2010, v. 47 n. 3, p. 273-275en_HK
dc.identifier.issn1386-6532en_HK
dc.identifier.urihttp://hdl.handle.net/10722/125562-
dc.description.abstractBackground: Enfuvirtide (ENF) is a viral fusion inhibitor used in patients failing highly active antiretroviral therapy (HAART). Mutations associated with ENF resistance have been identified within amino acid positions 36-45 of gp41. As ENF will be introduced to Hong Kong, an understanding of the prevalence of naturally occurred ENF resistance mutations is important before implementation of ENF treatment. Objectives: To investigate the prevalence of ENF resistance-associated mutations in the HR1 and HR2 of HIV-1 strains obtained from ENF-naïve patients. Study design: HIV-1 strains isolated from 185 patients (156 antiretroviral treatment [ART]-naïve and 29 HAART-experienced) were screened for ENF resistance-associated mutations using RT-PCR and DNA sequencing. Results: Primary mutations were detected in 19.4% of HARRT-experienced patients and 20.5% of ART-naïve patients. G36D was encountered most frequently and more prevalent in non-B subtypes. N42S, L54 M and V69I were the major polymorphisms detected. N42S and L54M were predominant in CRF01_AE and subtype B, respectively. V69I was found in all samples harboring G36D. In three longitudinal samples from an ENF-treated patient, G36D was detected after ENF treatment for 6 months and the mutation persisted after termination of ENF for 6 months. Conclusions: The high prevalence of ENF resistance-associated mutations in HARRT-experienced and ART-naïve patients identified in this study highlights the importance of mutation screening before ENF therapy in Hong Kong. Our findings from the ENF-treated patient showed that G36D mutation persisted as long as 6 months after ENF withdrawal. Phenotypic assays will be necessary to confirm the influence of this mutation to ENF susceptibility. © 2010 Elsevier B.V. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcven_HK
dc.relation.ispartofJournal of Clinical Virologyen_HK
dc.subjectEnfuvirtideen_HK
dc.subjectGp41en_HK
dc.subjectHAARTen_HK
dc.subjectHIVen_HK
dc.subject.meshAnti-HIV Agents - pharmacology-
dc.subject.meshDrug Resistance, Viral-
dc.subject.meshHIV Envelope Protein gp41 - genetics - pharmacology-
dc.subject.meshHIV Infections - virology-
dc.subject.meshHIV-1 - drug effects - genetics - isolation and purification-
dc.titleHigh prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kongen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1386-6532&volume=47&issue=3&spage=273&epage=275&date=2010&atitle=High+prevalence+of+primary+enfuvirtide+(ENF)+resistance-associated+mutations+in+HIV-1-infected+patients+in+Hong+Kongen_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.emailYam, WC:wcyam@hkucc.hku.hken_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.identifier.authorityYam, WC=rp00313en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jcv.2010.01.002en_HK
dc.identifier.pmid20116329-
dc.identifier.scopuseid_2-s2.0-76449107981en_HK
dc.identifier.hkuros173407en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-76449107981&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume47en_HK
dc.identifier.issue3en_HK
dc.identifier.spage273en_HK
dc.identifier.epage275en_HK
dc.identifier.isiWOS:000274862700015-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridLeung, PHM=7401747852en_HK
dc.identifier.scopusauthoridChen, JHK=35085819900en_HK
dc.identifier.scopusauthoridWong, KH=7404758411en_HK
dc.identifier.scopusauthoridChan, KC=35097079800en_HK
dc.identifier.scopusauthoridLam, HY=35097472400en_HK
dc.identifier.scopusauthoridCheng, VCC=23670479400en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridYam, WC=7004281720en_HK
dc.identifier.citeulike6637790-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats